Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

Haematologica. 2024 Aug 1;109(8):2693-2700. doi: 10.3324/haematol.2023.284678.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • COVID-19 Drug Treatment*
  • COVID-19* / complications
  • COVID-19* / mortality
  • Dexamethasone* / therapeutic use
  • Female
  • Hematologic Neoplasms* / drug therapy
  • Hematologic Neoplasms* / mortality
  • Humans
  • Male
  • Middle Aged
  • Registries*
  • SARS-CoV-2* / isolation & purification

Substances

  • Dexamethasone

Grants and funding

Funding: This study has been co-funded by the European Regional Development Fund (EDRD). CG-V [FIS PI21/01640] have received research grants from the Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III. The Project PI21/01640 has been funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work was co-funded by a research grant (SGR 01324 Q5856414G) from the AGAUR (Agencia de Gestión de Ayudas Universitarias y de Investigación) of Catalunya. A-TF has received a pre-doctoral grant supported by the Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III [RH RH042953].